Navigation Links
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
Date:5/13/2013

pan>Europe.

About Simeprevir
Simeprevir (TMC435) is an investigational NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells.

For additional information about simeprevir clinical studies, please visit www.clinicaltrials.gov.

About Hepatitis C 
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide - including approximately 3.2 million people in the United States - and 350,000 people per year die from the disease globally. When left untreated, hepatitis C can cause significant damage to the liver, including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which may include liver failure.

About Janssen Research & Development, LLC
Janssen Research & Development, LLC is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel medicines and solutions in five distinct therapeutic areas: Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research & Development, LLC visit www.janssenrnd.com.

(This press release contains "forward-looki
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Medina Medical announced today that Mr. ... the Board of Directors on August 18, 2014. Mr. ... commercialization experience, including over a decade of direct experience ... a Partner of the medical device incubator The Foundry, ... Foundry start-ups. Mr. Engelson previously served as the Chief ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... -- Research and Markets has announced the ... of Pharmaceutical Equipment Market in China, 2014-2018" report ... Trend Forecast of Pharmaceutical Equipment Market in ... pharmaceutical equipment industry in the aspects of ... business performance of domestic major enterprises, as well as ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... , , LAKE FOREST, Ill. ... leading developer and manufacturer of injectable pharmaceuticals announced today ... of Corvert ® from Pfizer Inc. , (Logo: ... Injection further demonstrates Bioniche Pharma,s continued growth and dedication ...
... CHARLOTTESVILLE, Virginia , January ... and Drug Administration (FDA) has licensed its,technology platform to help ... harmful side effects. , The FDA,s ... Research (CDER), will test the use of Biovista,s Adverse Event,Analysis ...
Cached Medicine Technology:Bioniche Pharma Launches Ibutilide Fumarate Injection 2Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative 2
(Date:8/30/2014)... York, New York (PRWEB) August 30, 2014 ... other incretin mimetic claims continue to move forward in ... statement issued by AstraZeneca PLC on July 31, 2014, ... been named in 409 product liability claims that allege ... Court documents indicate that many of these claims are ...
(Date:8/30/2014)... CO (PRWEB) August 30, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Lab Oven Industry, 2009-2019 is a professional and ... Oven industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, production value, and market ...
(Date:8/30/2014)... August 30, 2014 The federal ... lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific ... four cases selected for one of the proceeding’s ... August 18, 2014, U.S. District Judge Joseph R. ... disagrees with Boston Scientific’s contention that a consolidated ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s ... and increasingly difficult to get. Snoring and sleep apnea ... and breathing stops) robs people and their bed partners ... challenges. Up to 45% of the population snores and ... sleep apnea. Of these, only 10% have been diagnosed ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... CORONA, Calif., July 25 Watson,Pharmaceuticals, Inc. ... announced today that its subsidiary has commenced commercial,shipment ... the 40mg,strength from its Davie, Florida manufacturing facility. ... of marketing exclusivity for being the,first to file ...
... to benefit ALS Therapy Alliance to be presented at Fenway Park ... ... CVS/pharmacy announced today,that this year it has raised a record-breaking $4.4 ... research. This is,the seventh year of the annual fundraising effort which, to ...
... of New York will present an educational meeting regarding age-related macular ... the Farmingdale Public Library at 116 Merritts Road, Farmingdale, NY 11735, ... and refreshments will be provided. The phone number for pre-registration is ... ...
... at Wake Forest University Baptist Medical Center have disproved ... slows or stunts the immune system,s ability to restore ... of drugs known as the "cocktail." , Hepatitis ... leading to rapid liver damage, according to the Centers ...
... Experience it ... Are you an e-patient?,Studies show that 80 percent ... to Web 2.0, e-patients now have even more ways,to ... learn about,advanced medical technologies. Go to http://SutterHealth.org/annualreport ,and ...
... 24 AMICAS, Inc. (Nasdaq: AMCS ),a leader in ... will report the company,s financial results,for the second quarter ending ... 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... Tuesday, August 5, 2008 -- Call begins ...
Cached Medicine News:Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:AMICAS Schedules Second Quarter Earnings Call 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: